Because proximal tubules are also actively involved in glucose metabolism, sodium-glucose cotransporter-2 (SGLT2) inhibitors have been proposed to improve the prognosis of AKI as well as CKD9–11. This evidence concerns the gene SLC5A2 and acute kidney injury.